(redirected from Durezol)

difluprednate (ophthalmic)

(dye-floo-pred-nate) ,


(trade name)


Therapeutic: ocular agents
Pharmacologic: corticosteroids
Pregnancy Category: C


Treatment of inflammation and pain associated with ocular surgery.


Decreases inflammation.

Therapeutic effects

Decreased pain and inflammation following ocular surgery.


Absorption: Limited systemic absorption.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile



Contraindicated in: Active viral, mycobacterial or fungal infection of eyes and surrounding structures.
Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies potential risk to the fetus; Lactation: Use cautiously during lactation; Pediatric: Safety and effectiveness in children have not been established.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • ↑ intraocular pressure
  • blepharitis
  • cataracts
  • conjunctival hyperemia
  • corneal edema
  • delayed healing
  • eye pain
  • infections
  • iritis
  • photophobia


Drug-Drug interaction

None noted.


Ophthalmic (Adults) 1 drop four times daily, starting 24 hr after surgery for 2 wk, then twice daily for one week, then further tapered based on response.


Ophthamic emulsion: 0.05% in 5 mL bottle

Nursing implications

Nursing assessment

  • Assess affected eye for pain and swelling during therapy.
  • Monitor intraocular pressure of difluprednate is used more than 10 days.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Ophthalmic: Instill 1 drop into conjunctival sac of affected eye 4 times/day beginning 24 hrs after surgery and continuing throughout first 2 wks of postoperative period, followed by twice daily for a wk, then base dose on patient response.

Patient/Family Teaching

  • Instruct patient in correct technique and frequency for instillation of eye drops (see ).
  • Instruct patient to avoid wearing contact lenses during therapy.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
  • Advise patient to notify health care professional if redness, itching or inflammation develops or becomes aggravated.

Evaluation/Desired Outcomes

  • Decrease in eye pain and inflammation following ocular surgery.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
There are no human eye data for five topical corticosteroids: difluprednate (Durezol), fluorometholone (Flarex, Fluor-OP, FML), loteprednol (Alrex, Lotemax), prednisolone (Econopred), and rimexolone (Vexol).
Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery.
along with difluprednate 0.05% (Durezol) every hour and loteprednol etabonate 0.5% (Lotemax) ointment at night in each eye.
Medications at that time included Xibron drops, a NSAID to reduce swelling, Durezol drops, a topical corticosteroid, Cornbigan drops, and oral Voltaren.
30 March 2010 - Swiss eye care company Alcon Inc (NYSE: ACL) said yesterday that it has obtained regulatory approval and finalised the acquisition of the rights in the US for DUREZOL emulsion, and the global rights, excluding Latin America, for ZYCLORIN from Sirion Therapeutics Inc.
Alcon will immediately assume all marketing, promotion and sales of DUREZOL. The company's management said that it is continuing to evaluate options to acquire ZIRGAN, an antiviral recently approved by the US Food and Drug Administration (FDA) for the treatment of acute herpetic keratitis (corneal ulcers).
DUREZOL emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery and received FDA approval in 2008.
Both products have the approval of the US Food and Drug Administration (FDA) and are already on the market.aA Durezol is approved for the treatment of inflammation and pain resulting from eye surgery.